Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at Wolfe Research

Equities research analysts at Wolfe Research assumed coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a report released on Thursday. The brokerage set a “peer perform” rating on the stock.

A number of other analysts have also commented on GPCR. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reduced their price objective on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 16th. JPMorgan Chase & Co. boosted their target price on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Finally, Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Trading Down 0.6%

NASDAQ:GPCR opened at $47.84 on Thursday. The firm has a fifty day simple moving average of $70.42 and a two-hundred day simple moving average of $51.25. The stock has a market capitalization of $3.39 billion, a price-to-earnings ratio of -60.55 and a beta of -1.80. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Institutional investors have recently made changes to their positions in the company. Morgan Stanley boosted its stake in Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Structure Therapeutics by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after purchasing an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC purchased a new position in Structure Therapeutics in the fourth quarter valued at approximately $61,086,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.